Professor, Dermatology School of Medicine and Biological Chemistry; Vice Chair for Research, Dermatology School of Medicine; Co-Director, BIDD Program, Chao Family; Equity Advisor, School of Medicine
University of California, Irvine
CDC42 RHOJ Interaction Inhibitors for the Treatment of Neurofibromatosis
Neurofibromatosis type 2 (NF2) tumors can cause significant hearing loss and current therapies can accelerate this loss through the impact of side effects and non compliance. Using cell lines provided by the Children’s Brain Tumor Network, researchers are testing new treatments to address this issue.